Discover 1,440 paid clinical trials in Quebec. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Filter
1
Filter results
Results: 1,440
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
for
HER2-positive Breast Cancer
Location: Shirley NY, Quebec, Albany NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07413939
Phase2, Phase3, Recruiting
Featured
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
for
Ulcerative Colitis
Location: London, Fresh Meadows NY, Montreal, Monroe NC,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06979336
Phase2, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
for
Von Willebrand Disease, Type 3
Location: Montreal, Richmond VA, Toronto, Gainesville FL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0+
Code: NCT06998524
Phase3, Recruiting
Featured
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Moncton, The Bronx NY, New York NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Rimouski, Boston MA, New Haven CT, Quebec,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase3, Recruiting
Active & Responsive
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
for
Amyotrophic Lateral Sclerosis
Location: Boston MA, New York NY, Montreal, Philadelphia PA,
Sponsor: Prilenia
Sex: All
Age: 18 - 70+
Code: NCT07322003
Phase3, Recruiting
Active & Responsive
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
for
Intestinal Neoplasms, Gastrointestinal Neoplasms,
Location: Topsham ME, Westbrook ME, Boston MA, Newton MA,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07222800
Phase3, Recruiting
Active & Responsive
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
for
Alzheimer's Disease
Location: Halifax, East Providence RI, Newton MA, Quebec,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 60 - 70+
Code: NCT06976216
Phase3, Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Waterford CT, Guilford CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Location: Providence RI, New Haven CT, Quebec, New York NY,
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT06647498
Phase2, Phase3, Recruiting
Active & Responsive
Treatment Interrupts Depression Early
for
Depression
Location: Halifax, Montreal
Sponsor: Nova Scotia Health Authority
Sex: All
Age: 12 - 25
Code: NCT05002309
Phase2, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: New Bedford MA, New Haven CT, Manhasset NY, New York NY,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
for
NASH - Nonalcoholic Steatohepatitis,
Location: South Dartmouth MA, New Haven CT, Manhasset NY,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06528314
Phase3, Recruiting
Active & Responsive
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
for
Non-Small Cell Lung Cancer
Location: Neptune City NJ, Montreal, Syracuse NY, Ottawa, Toronto,
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 18+
Code: NCT02468024
Phase3, Recruiting
Active & Responsive
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
for
HIV-1-infection
Location: Flushing NY, Brooklyn NY, New York NY, Newark NJ,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT07645287
Phase2, Recruiting
Active & Responsive
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation